EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Acquired immunity against SARS‐CoV‐2 infection and vaccination

Laurent Renia iD, Lisa Fp Ng iD

EMBO Molecular Medicine · 2023

DOI: 10.15252/emmm.202216345 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EMBO Molecular Medicine, 2023. Verfasst von Laurent Renia und 1 weiteren Autor:innen. Beteiligte Einrichtung: Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: A*ccelerate, A*STAR, ACruse, A*STAR, Biomedical Research Council, A*STAR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ongoing severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic has caused more than 700 million confirmed infections and ~7 million fatalities worldwide since its emergence in December 2019. SARS‐CoV‐2 is part of a family of positive‐sense, enveloped RNA viruses known as coronaviruses. Today, at least seven human coronaviruses have been identified and are known to cause respiratory tract illnesses with varying severity. The COVID‐19 pandemic spurred the generation of a vast amount of scientific knowledge on coronaviruses in record time, leading to a broad understanding of host immunity against SARS‐CoV‐2, and the rapid development of life‐saving vaccines (mainly mRNA and adenovirus‐ or inactivated virus‐based vaccines). Real world data on licensed SARS‐CoV‐2 vaccines have shown that efficacy ranges from 50 to 95% depending on viral variants, pre‐infections, and vaccine formulations, regimens, and combinations. While vaccination does markedly decrease the chances of infection and severe disease, breakthrough symptomatic and asymptomatic infections have occurred due to the emergence of immune escape virus variants. Therefore, despite these early successes, a better understanding of the mechanisms of protective immunity against infection is essential for the development of longer lasting and more efficient vaccines against SARS‐CoV‐2 and future coronaviruses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansCOVID-19 VaccinesSARS-CoV-2PandemicsVaccinationAdaptive Immunity

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
  • A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

ORCID-Profile: Laurent Renia, Lisa Fp Ng

Förderung

  • A*ccelerate, A*STAR
  • ACruse, A*STAR
  • Biomedical Research Council, A*STAR
  • Singapore Ministry of Education
  • Singapore National Medical Research -COVID Research fund
  • TF IPC Ltd
  • US Food and Drug Administration
  • Biomedical Research Council

Zitieren

APA

Renia, L., & Ng, L. F. (2023). Acquired immunity against SARS‐CoV‐2 infection and vaccination. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202216345

Vancouver

Renia L, Ng LF. Acquired immunity against SARS‐CoV‐2 infection and vaccination. EMBO Molecular Medicine. 2023. doi:10.15252/emmm.202216345

BibTeX
@article{Renia2023,
  author = {Renia, Laurent and Ng, Lisa Fp},
  title = {Acquired immunity against SARS‐CoV‐2 infection and vaccination},
  journal = {EMBO Molecular Medicine},
  year = {2023},
  doi = {10.15252/emmm.202216345}
}
Kostenlos starten →